Q1 Drug Sales, Pipeline, 2019 Catalysts Top Themes For AstraZeneca Update
Executive Summary
Q1 Earnings Preview: When AstraZeneca reports first-quarter results on April 26 investor focus will be on new product sales growth, pipeline catalysts and clues on possible fresh divestment and licensing deals.
You may also be interested in...
AstraZeneca CEO: Explosive Q1 China Growth Will Ease In 2H, Then Reignite
AstraZeneca generated 28% sales growth in China during the first quarter - but the UK group's CEO said that stellar performance will decline somewhat in the second half.
Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset
AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.
Tagrisso Climbs Close To Top Of AstraZeneca Sales Tree
The drug major has presented a set of financials that have comfortably surpassed analyst forecasts and show that its new oncology therapies now make up around 30% of group sales and are growing strongly.